Topic: Immunotherapeutic Approaches for Treatment of Brain Tumors

Download All Articles

A special issue of Neuroimmunology and Neuroinflammation  (Print ISSN:2347-8659; Online ISSN:2349-6142).

Deadline for manuscript submissions: 31 Jul 2018

Share This Special Issue

Guest Editor(s)

  • Dr. Terry Lichtor, MD, PhD
    Associate Professor, Neurological Surgery, Rush University, Rush Medical College, Rush University Medical Center in Chicago, Illinois, USA.

    Website | E-mail

Special Issue Introduction:

Antigenic differences between normal and malignant cells of the cancer patient form the rationale for clinical immunotherapeutic strategies. One emerging strategy in the treatment of tumors involves stimulation of an immunologic response against the neoplastic cells. Tumor cells may evade immune responses by losing expression of antigens or major histocompatiblity complex (MHC) molecules or by producing immunosuppressive cytokines. A variety of strategies have been used to increase the immunogenetic properties of vaccine therapies for brain tumors. The immune response can be augmented by genetic modification of tumor cells to secrete cytokines including IL-2, GM-CSF and interferon-γ. Alternatively, one can genetically modify the tumor cells to express co-stimulatory molecules such as B7.
Modification of neoplastic cells taken directly from tumor-bearing patients may be difficult. An alternative cell type that can be used for therapeutic immunizations is the dendritic cell (DC), which is a specialized antigen presenting cell. Pre-clinical studies have indicated that immunization with DC pulsed with tumor cell antigens can stimulate a cytotoxic T cell response that is tumor-specific and that engenders protective immunity against CNS tumors. Another strategy is to transfect genomic DNA from the malignant cells into a fibroblast cell line which results in stable integration and expression of the transferred DNA. Immunization of tumor-bearing mice with the DNA-based vaccine results in the induction of cell mediated immunity directed toward the type of tumor from which the DNA was obtained along with prolongation of survival.
The ultimate goal of cancer therapy is the elimination of every remaining tumor cell from the patient. It is unlikely that a single form of therapy is capable of achieving this goal. However, immunotherapy in combination with surgery, radiation therapy and chemotherapy will likely find a place as a new and important means of treatment for patients with brain tumors. For this special issue papers are being solicited that explore the potential of different immunotherapeutic strategies for the treatment of brain tumors along with related aspects of tumor immunotherapy.

Keywords:

Immunotherapy, brain tumors, tumor vaccine, immune suppression, tumor growth, gene therapy

Submission Information:

For Author Instructions, please refer to http://nnjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.editorialmanager.com/neurimm/default.aspx
Submission Deadline: 31 Jul 2018
Contacts: Nancy Ding, Assistant Editor, editor002@nnjournal.net

Published Articles Download All Articles
  • Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma

    Caleb J. Yelton , Swapan K. Ray
    Glioblastoma multiforme (GBM), which is the most common primary central nervous system malignancy in adults, has long presented a formidable challenge to researchers and clinicians alike. Dismal 5-year survival rates of the patients with these tumors and the ability of the recurrent tumors to evade primary treatment strategies have prompted a need for alternative therapies in the treatment of... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:46. | doi:10.20517/2347-8659.2018.58
    Published on: 12 Nov 2018  | Viewed:65  | Downloaded:3
    +HTML| PDF
  • Total tumor RNA pulsed dendritic cells plus adoptive transfer of ex-vivo enriched autologous T-lymphocytes in the treatment of children with primary brain tumors

    Sridharan Gururangan , Elias Elias Sayour , Duane A. Mitchell
    The therapeutic approach of adoptive lymphocyte transfer (ALT) using lymphocytes primed and expanded ex-vivo by exposure to total tumor RNA (ttRNA) containing dendritic cells (DCs) and administered after lymphodepletive host conditioning in patients with refractory melanoma with brain metastases has shown excellent objective responses indicating that the central nervous system (CNS) is not an... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:45. | doi:10.20517/2347-8659.2018.44
    Published on: 29 Oct 2018  | Viewed:183  | Downloaded:5
    +HTML| PDF
  • It takes two: potential therapies and insights involving microglia and macrophages in glioblastoma

    John Choi , Nicholas Mai , Christopher Jackson , Zineb Belcaid , Michael Lim
    Microglia and macrophages, two myeloid cell lineages with different origins, make up the majority of immune cells present in glioblastoma (GBM). However, much of the literature does not distinguish between microglia and macrophages, despite a growing body of evidence that demonstrates key structural and functional differences between the cell types. Furthermore, the current M1/M2 paradigm used... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:42. | doi:10.20517/2347-8659.2018.47
    Published on: 18 Oct 2018  | Viewed:469  | Downloaded:33
    +HTML| PDF
  • CAR-T cell therapy in neuro-oncology: applications and toxicity

    Akanksha Sharma , Gustavo De Leon , Alyx Porter , Marie F Grill , Allison Rosenthal , Christine E Brown , Kristin Swanson , Maciej M Mrugala
    A new era for cancer treatment has been ushered in with the field of cancer immunotherapy. After initial success with systemic malignancies, several of these promising treatments are being investigated for efficacy with primary and secondary brain tumors. Chimeric antigen receptor (CAR) T cells are being studied, both with systemic infusion and direct administration to the tumor and into the... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:43. | doi:10.20517/2347-8659.2018.51
    Published on: 18 Oct 2018  | Viewed:424  | Downloaded:20
    +HTML| PDF
  • Glioma associated microglia/macrophages, a potential pharmacological target to promote antitumor inflammatory immune response in the treatment of glioblastoma

    Cinzia Dello Russo , Natalia Cappoli
    Glioma associated microglia/macrophages (GAMs) constitute the largest proportion of glioma infiltrating cells, particularly in high grade tumors (i.e., glioblastoma). Once inside the tumors, GAMs usually acquire a specific phenotype of activation that favors tumor growth, angiogenesis and promotes the invasion of normal brain parenchyma. Therefore, treatments that limit or prevent GAMs’... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:36. | doi:10.20517/2347-8659.2018.42
    Published on: 20 Sep 2018  | Viewed:700  | Downloaded:55
    +HTML| PDF
  • The novel-molecule T11TS facilitated arousal of glioma-mediated dormancy of bone-marrow hematopoietic stem-cells

    Somnath Mondal , Ankur Datta , Iman Hazra , Sk Md Omar Faruk , Saibal Moitra , Suhnrita Chaudhuri , Lakshyajeet Nath , Prasanta Kumar Das , Anjan Kumar Basu , Santanu Kumar Tripathi , Swapna Chaudhuri
    Aim: T11TS, a potent anti-gliomagenic glycoprotein, stimulates both peripheral and intracranial immune response. The status of bone marrow hematopoietic stem cells (BMHSCs), the cradle of regeneration of all blood cells, during gliomagenic global immune devastations has not yet been investigated. Therefore, we aimed to delineate the effects of T11TS on immature and mature compartments of... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:34. | doi:10.20517/2347-8659.2018.13
    Published on: 30 Aug 2018  | Viewed:617  | Downloaded:21
    +HTML| PDF
  • Systemic therapy in patients with NSCLC with brain metastasis: the emerging role of immunotherapy

    Jiaxin Niu , Junle Zhou , Sara Lindebak , Fade Mahmoud
    Brain metastasis (BM) is very common in advanced non-small cell lung cancer (NSCLC) patients. The development of BM remains a serious complication associated with significant morbidity and mortality. The traditional approach has been largely focusing on local therapy with surgery and/or radiation. New approaches to treat BM in NSCLC are urgently needed to offer safe and effective therapy as... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:32. | doi:10.20517/2347-8659.2018.39
    Published on: 23 Aug 2018  | Viewed:562  | Downloaded:82
    +HTML| PDF
  • Immunotherapy for pediatric brain tumors

    Daniel B. Landi , Eric M. Thompson , David M. Ashley
    Immunotherapy, while effective against lymphoid cancers and some solid tumors, has shown less benefit against pediatric brain tumors. Tumor heterogeneity, a suppressive immune microenvironment, and the blood-brain barrier have the potential to diminish any immune-based approach and limit efficacy. More importantly, most pediatric brain tumors are immunologically quiescent, stemming from a low... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:29. | doi:10.20517/2347-8659.2018.35
    Published on: 23 Jul 2018  | Viewed:1803  | Downloaded:146
    +HTML| PDF
  • Photodynamic therapy mediated immune therapy of brain tumors

    Henry Hirschberg , Kristian Berg , Qian Peng
    Photodynamic therapy of tumors requires the topical, systemic or oral administration of a photosensitizing compound,illumination of the tumor area by light of a specific wavelength and the presence of oxygen. Light activation of the photosensitizer transfers energy to molecular oxygen creating singlet oxygen, a highly reactive and toxic species that rapidly reacts with cellular components... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:27. | doi:10.20517/2347-8659.2018.31
    Published on: 10 Jul 2018  | Viewed:1560  | Downloaded:84
    +HTML| PDF
  • Classification of brain tumor using devernay sub-pixel edge detection and k-nearest neighbours methodology

    Ayush Arora , Ritesh Kumar , Shubham Tiwari , Mysore Shwetha , Selvam Venkatesan , Ramesh Babu
    Any disease can be treated only once it is imaged, detected and classified. This paper proposes a set of algorithms for classification of a brain tumor with better accuracy and efficiency. The proposal uses a JPEG format of the DICOM image fed into three stages namely pre-processing, segmentation using sub-pixel edge detection method and using the nearest neighbor methodology for the detection... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:26. | doi:10.20517/2347-8659.2018.11
    Published on: 19 Jun 2018  | Viewed:780  | Downloaded:32
    +HTML| PDF
  • A concise review of immunotherapy for glioblastoma

    Omer Sager , Ferrat Dincoglan , Selcuk Demiral , Bora Uysal , Hakan Gamsiz , Bahar Dirican , Murat Beyzadeoglu
    Glioblastoma (GB) is the most common and aggressive form of primary brain tumors in adults with a universally poor prognosis despite multimodal management including surgery, chemotherapy and radiation therapy. Among the novel therapeutic strategies, immunotherapy deserves particular attention with its potential to evoke biologic response and harness the host immune system. Considerable success... Read more
    This article belongs to the Special Issue Immunotherapeutic Approaches for Treatment of Brain Tumors
    Neuroimmunol Neuroinflammation 2018;5:25. | doi:10.20517/2347-8659.2018.12
    Published on: 15 Jun 2018  | Viewed:930  | Downloaded:128
    +HTML| PDF
Neuroimmunology and Neuroinflammation ISSN 2349-6142 (Online), ISSN 2347-8659 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.